Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics

BACKGROUND: Glioblastoma (GBM) represents nearly one-half of primary brain tumors, and the median survival of patients with GBM is only 14.6 months. Surgery followed by radiation with concomitant temozolomide (TMZ) therapy is currently the standard of care. However, an increasing body of evidence su...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hao, Li, Chunlin, Hu, Haiyang, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389719/
https://www.ncbi.nlm.nih.gov/pubmed/35982414
http://dx.doi.org/10.1186/s12860-022-00438-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389719/
https://www.ncbi.nlm.nih.gov/pubmed/35982414
http://dx.doi.org/10.1186/s12860-022-00438-1

Ejemplares similares